approval
saveTAFINLAR (DABRAFENIB MESYLATE) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL
view source ↗Data sources
last refreshed 6mo ago
Found something off?
drug timeline · 8
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 232d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 232d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 585d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 585d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 604d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 604d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 616d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 616d ago
same company · ±60 days · 6
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalMar 29, 2024
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 29, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB) — FDA approvalMar 29, 2024
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 4, 2024
- approvalKESIMPTA: KESIMPTA (OFATUMUMAB) — FDA approvalApr 12, 2024
- approvalImatinib Mesylate Shilpa: GLEEVEC (IMATINIB MESYLATE) — FDA approvalMar 1, 2024
comments(0)
5-min edit window · permanent after that